Archive: News
-
Ruesch Center and OncLive Recognize Former VP Biden at the Luminary Awards
Former Vice President Joe Biden was among those who were recognized for improving the lives of patients with gastrointestinal cancer at the Second Annual Luminary Awards, hosted by the Ruesch Center and OncLive.
Category: News
-
Discussing Drug Development & Complexity in Clinical Trials at the 9th Annual Ruesch Symposium
At a panel discussion on innovation and challenges in clinical research, panelist discussed difficulties related to planning clinical trials for patients with rare tumor types within the existing paradigm.
Category: News
-
OncLive® and The Ruesch Center for the Cure of Gastrointestinal Cancers Honored the 2018 Honorees of the Second Annual Luminary Awards in GI Cancers
OncLive® and The Ruesch Center, the founding partners of the Luminary Awards in GI Cancers, congratulate the 2018 honorees recognized at the Second Annual Luminary Awards ceremony, which was held Thursday, Nov. 29 in Washington, D.C.
Category: News
-
Marshall Explains Recent Trial Data in Terms of the Evolving Landscape of Pancreatic Cancer
During a Targeted Oncology case-based peer perspectives program, John Marshall, MD, reviewed his clinical considerations for the management of pancreatic cancer.
Category: News
-
Luminary Awards in GI Cancers Honor Distinguished Leaders
At the 2nd Annual Luminary Awards, hosted by OncLive and The Ruesch Center for the Cure of Gastrointestinal Cancers, several individuals in the cancer care community were honored for their efforts in improving the lives of patients with gastrointestinal cancers.
Category: News
-
ASCO Chief Medical Officer Dr. Richard L. Schilsky Honored with Award in Gastrointestinal Cancers
ASCO’s chief medical officer Richard L. Schilsky, MD, FACP, FASCO, is among the five gastrointestinal (GI) oncology professionals honored with OncLive® and The Ruesch Center for the Cure of Gastrointestinal Cancers’ 2018 Luminary Awards in GI Cancers.
Category: News
-
TGen leader earns award for advances in treating pancreatic cancer
Dr. Daniel D. Von Hoff, Distinguished Professor and Physician-In-Chief of the Translational Genomics Research Institute (TGen), an affiliate of the City of Hope, is one of five leading researchers who will receive a Luminary Award in GI Cancers from OncLive and The Ruesch Center for the Cure of Gastrointestinal Cancers.
Category: News
-
Atezolizumab Plus Bevacizumab Shows Durable Activity in Advanced HCC
The combination of the PD-L1 inhibitor atezolizumab (Tecentriq) and the VEGF inhibitor bevacizumab (Avastin) showed promising and durable antitumor activity in a phase Ib study of patients with advanced hepatocellular carcinoma (HCC).
Category: News
-
Update on HCC treatment by Dr. Aiwu Ruth He
Dr. Aiwu Ruth He summarizes the highlights of ILCA 2018 and provides updates in HCC treatment.
Category: News
-
OncLive® and The Ruesch Center to Host the Second Annual Luminary Awards in GI Cancers
The awards honor individuals who are making a difference in the gastrointestinal cancers community.
Category: News